The Tisch Cancer Institute at Mount Sinai | Strategic Alliance Partners

December 28, 2020

Joshua Brody, MD, discusses established and upcoming immunotherapies in the lymphoid malignancy pipeline.

December 03, 2020

Joshua Brody, MD, discusses the expanding role of venetoclax in mantle cell lymphoma.

December 02, 2020

John O. Mascarenhas, MD, discusses the role of genetic testing in myeloproliferative neoplasms.

November 25, 2020

Joshua Brody, MD, discusses management strategies for the toxicities associated with CAR T-cell therapy in mantle cell lymphoma.

November 19, 2020

Joshua Brody, MD, discusses advances made with CAR T-cell therapy in MCL, the promise of venetoclax in B-cell malignancies, and the potential for bispecific antibody combination regimens in this disease.

November 18, 2020

Joshua Brody, MD, discusses the potential role for bispecific antibodies in mantle cell lymphoma.

November 12, 2020

Joshua Brody, MD, discusses the challenges of mitigating antigen escape in mantle cell lymphoma.

November 11, 2020

Miriam Merad, MD, PhD, discusses how her explorations of the role of inflammation in patients with cancer translated into critical insights for patients with COVID-19.

October 30, 2020

Nicholas Rohs, MD, discusses the progress made with chemoimmunotherapy combinations in frontline non–small cell lung cancer, future research directions, and emerging approaches that seek to propel progress in this disease.

October 29, 2020

Edward Wolin, MD, discusses the current treatment landscape of neuroendocrine tumors.

October 07, 2020

Deborah B. Doroshow, MD, PhD, discusses the impact of the coronavirus disease 2019 pandemic on cancer care.

September 29, 2020

Deirdre J. Cohen, MD, MS, an expert in pancreatic and other gastrointestinal cancers as well as an accomplished clinical trial leader, has joined Mount Sinai Health System as Director of the Gastrointestinal Oncology Program and Medical Director of the Cancer Clinical Trials Office at The Tisch Cancer Institute.

September 25, 2020

John O. Mascarenhas, MD, discusses the need to develop curative therapies in myelofibrosis.

September 16, 2020

Joshua Richter, MD, discusses the importance of optimizing these novel therapies to make way for precision medicine in multiple myeloma.

September 10, 2020

John O. Mascarenhas, MD, discusses the potential role of pacritinib in myeloproliferative neoplasms.

September 08, 2020

Shambavi Richard, MD, discusses the benefit of adding daratumumab to lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma.

September 08, 2020

Ajai Chari, MD, discusses the approval of belantamab mafodotin-blmf in ​relapsed/refractory multiple myeloma. 

September 02, 2020

Joshua Richter, MD, discusses the importance of optimizing available therapies in multiple myeloma. 

September 01, 2020

Shambavi Richard, MD, highlights the rapidly evolving armamentarium ​in multiple myeloma.

August 31, 2020

Joshua Richter, MD, discusses the utility of isatuximab in relapsed/refractory multiple myeloma.